The amount of the deal was not disclosed.
The round was led by existing investor Dental Innovations BVBA with participation from Sailing Capital, Longitude Capital Management and other current investors.
Led by Chief Executive Officer Murthy Simhambhatla, Alphaeon is a privately held company focused on bringing innovative products and services to the aesthetics market. Its lead product candidate is DWP-450, a Botulinum toxin Type A for the treatment of glabellar lines.
In addition to the funds provided at closing, future tranches of financing are subject to regulatory milestones related to its DWP-450 (Botulinum toxin Type A) product candidate for the treatment of adult patients with glabellar lines, also known as frown lines between the eyebrows.
FinSMEs
07/05/2017